Serveur d'exploration sur la glutarédoxine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

[Proliferation and apoptosis of lung cancer cells regulated by gultaredoxin 3].

Identifieur interne : 000197 ( Main/Exploration ); précédent : 000196; suivant : 000198

[Proliferation and apoptosis of lung cancer cells regulated by gultaredoxin 3].

Auteurs : Y Y Zhu [République populaire de Chine] ; Z J Wang [République populaire de Chine] ; N. Ma [République populaire de Chine] ; J W Zhou [République populaire de Chine]

Source :

RBID : pubmed:29860757

Descripteurs français

English descriptors

Abstract

Objective: To investigate the effects of inhibiting glutaredoxin 3(GLRX3) expression on proliferation and apoptosis of lung cancer cells. Methods: Western blotting was used to detect the expressions of GLRX3 protein in human embryonic lung fibroblast MRC5 and lung cancer cells, including A427, A549, PC9 and H1299. GLRX3-targeted siRNA (experimental group) and negative siRNA (negative group) were transfected into A549 cells, and the cells without special treatment were blank group. The protein expression levels of GLRX3, cleaved cysteinyl aspartate specific proteinase 3(cleaved caspase-3), signal transducers and activators of transcription 3(STAT3), phosphorylated STAT3(p-STAT3) in each group at 48 hours after transfection were measured by Western blotting. The proliferation ability of differently treated cells at 24 hours, 48 hours and 72 hours after transfection were detected by CCK-8 array. The cell apoptosis at 48 hours after transfection was evaluated by flow cytometry. Results: The protein expression levels of GLRX3 in MRC5, A427, A549, PC9 and H1299 were 0.094±0.010, 0.282±0.021, 0.551±0.045, 0.423±0.039 and 0.454±0.036, respectively. The protein expressions of GLRX3 in tested lung cancer cells were significantly higher than that of MRC5 cells (all P<0.01). The GLRX3 protein expressions in blank group, negative control group and experimental group at 48 hours after transfection were 0.311±0.029, 0.328±0.032 and 0.103±0.012, respectively. GLRX3 protein expression level of experimental group in A549 cells was significantly lower than that of control group (P<0.01), whilewithout statistical difference between the negative group and blank group (P>0.05). A values of experimental group at 24, 48 and 72 hours after transfection in A549 cells were significantly different from those of blank group (all P<0.01). Percent of apoptotic cells in the experimental group was (9.52±0.56)%, which was significantly higher than that of blank group [(1.65±0.22)%] and negative control group [(1.42±0.26)%, all P<0.01]. Consistently, compared with blank group, the cleaved caspase-3 markedly increased in the experimental group (P<0.01). The protein expression of p-STAT3 in the experimental group was significantly lower than the blank group (P<0.01), while no significant difference of STAT3 protein expression was observed among all the groups (P>0.05). Conclusions: Inhibition of GLRX3 gene expression can inhibit the proliferation of lung cancer cells and induce cell apoptosis through up-regulating cleaved caspase-3 expression and down-regulating STAT3 signaling pathway.

DOI: 10.3760/cma.j.issn.0253-3766.2018.05.002
PubMed: 29860757


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">[Proliferation and apoptosis of lung cancer cells regulated by gultaredoxin 3].</title>
<author>
<name sortKey="Zhu, Y Y" sort="Zhu, Y Y" uniqKey="Zhu Y" first="Y Y" last="Zhu">Y Y Zhu</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003</wicri:regionArea>
<wicri:noRegion>Zhengzhou 450003</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Wang, Z J" sort="Wang, Z J" uniqKey="Wang Z" first="Z J" last="Wang">Z J Wang</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003</wicri:regionArea>
<wicri:noRegion>Zhengzhou 450003</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ma, N" sort="Ma, N" uniqKey="Ma N" first="N" last="Ma">N. Ma</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003</wicri:regionArea>
<wicri:noRegion>Zhengzhou 450003</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Zhou, J W" sort="Zhou, J W" uniqKey="Zhou J" first="J W" last="Zhou">J W Zhou</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003</wicri:regionArea>
<wicri:noRegion>Zhengzhou 450003</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29860757</idno>
<idno type="pmid">29860757</idno>
<idno type="doi">10.3760/cma.j.issn.0253-3766.2018.05.002</idno>
<idno type="wicri:Area/Main/Corpus">000236</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000236</idno>
<idno type="wicri:Area/Main/Curation">000236</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000236</idno>
<idno type="wicri:Area/Main/Exploration">000236</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">[Proliferation and apoptosis of lung cancer cells regulated by gultaredoxin 3].</title>
<author>
<name sortKey="Zhu, Y Y" sort="Zhu, Y Y" uniqKey="Zhu Y" first="Y Y" last="Zhu">Y Y Zhu</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003</wicri:regionArea>
<wicri:noRegion>Zhengzhou 450003</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Wang, Z J" sort="Wang, Z J" uniqKey="Wang Z" first="Z J" last="Wang">Z J Wang</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003</wicri:regionArea>
<wicri:noRegion>Zhengzhou 450003</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Ma, N" sort="Ma, N" uniqKey="Ma N" first="N" last="Ma">N. Ma</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003</wicri:regionArea>
<wicri:noRegion>Zhengzhou 450003</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Zhou, J W" sort="Zhou, J W" uniqKey="Zhou J" first="J W" last="Zhou">J W Zhou</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003</wicri:regionArea>
<wicri:noRegion>Zhengzhou 450003</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Zhonghua zhong liu za zhi [Chinese journal of oncology]</title>
<idno type="ISSN">0253-3766</idno>
<imprint>
<date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Apoptosis (physiology)</term>
<term>Carrier Proteins (antagonists & inhibitors)</term>
<term>Carrier Proteins (metabolism)</term>
<term>Caspase 3 (metabolism)</term>
<term>Cell Count (MeSH)</term>
<term>Cell Line, Tumor (MeSH)</term>
<term>Cell Proliferation (physiology)</term>
<term>Down-Regulation (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Lung Neoplasms (metabolism)</term>
<term>Lung Neoplasms (pathology)</term>
<term>Lung Neoplasms (physiopathology)</term>
<term>Neoplasm Proteins (antagonists & inhibitors)</term>
<term>Neoplasm Proteins (metabolism)</term>
<term>RNA, Small Interfering (MeSH)</term>
<term>STAT3 Transcription Factor (metabolism)</term>
<term>Signal Transduction (MeSH)</term>
<term>Transfection (MeSH)</term>
<term>Up-Regulation (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Apoptose (physiologie)</term>
<term>Caspase-3 (métabolisme)</term>
<term>Facteur de transcription STAT-3 (métabolisme)</term>
<term>Humains (MeSH)</term>
<term>Lignée cellulaire tumorale (MeSH)</term>
<term>Numération cellulaire (MeSH)</term>
<term>Petit ARN interférent (MeSH)</term>
<term>Prolifération cellulaire (physiologie)</term>
<term>Protéines de transport (antagonistes et inhibiteurs)</term>
<term>Protéines de transport (métabolisme)</term>
<term>Protéines tumorales (antagonistes et inhibiteurs)</term>
<term>Protéines tumorales (métabolisme)</term>
<term>Régulation négative (MeSH)</term>
<term>Régulation positive (MeSH)</term>
<term>Transduction du signal (MeSH)</term>
<term>Transfection (MeSH)</term>
<term>Tumeurs du poumon (anatomopathologie)</term>
<term>Tumeurs du poumon (métabolisme)</term>
<term>Tumeurs du poumon (physiopathologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>Carrier Proteins</term>
<term>Neoplasm Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Carrier Proteins</term>
<term>Caspase 3</term>
<term>Neoplasm Proteins</term>
<term>STAT3 Transcription Factor</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Protéines de transport</term>
<term>Protéines tumorales</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Caspase-3</term>
<term>Facteur de transcription STAT-3</term>
<term>Protéines de transport</term>
<term>Protéines tumorales</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Apoptose</term>
<term>Prolifération cellulaire</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Apoptosis</term>
<term>Cell Proliferation</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr">
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Cell Count</term>
<term>Cell Line, Tumor</term>
<term>Down-Regulation</term>
<term>Humans</term>
<term>RNA, Small Interfering</term>
<term>Signal Transduction</term>
<term>Transfection</term>
<term>Up-Regulation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Numération cellulaire</term>
<term>Petit ARN interférent</term>
<term>Régulation négative</term>
<term>Régulation positive</term>
<term>Transduction du signal</term>
<term>Transfection</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<b>Objective:</b>
To investigate the effects of inhibiting glutaredoxin 3(GLRX3) expression on proliferation and apoptosis of lung cancer cells.
<b>Methods:</b>
Western blotting was used to detect the expressions of GLRX3 protein in human embryonic lung fibroblast MRC5 and lung cancer cells, including A427, A549, PC9 and H1299. GLRX3-targeted siRNA (experimental group) and negative siRNA (negative group) were transfected into A549 cells, and the cells without special treatment were blank group. The protein expression levels of GLRX3, cleaved cysteinyl aspartate specific proteinase 3(cleaved caspase-3), signal transducers and activators of transcription 3(STAT3), phosphorylated STAT3(p-STAT3) in each group at 48 hours after transfection were measured by Western blotting. The proliferation ability of differently treated cells at 24 hours, 48 hours and 72 hours after transfection were detected by CCK-8 array. The cell apoptosis at 48 hours after transfection was evaluated by flow cytometry.
<b>Results:</b>
The protein expression levels of GLRX3 in MRC5, A427, A549, PC9 and H1299 were 0.094±0.010, 0.282±0.021, 0.551±0.045, 0.423±0.039 and 0.454±0.036, respectively. The protein expressions of GLRX3 in tested lung cancer cells were significantly higher than that of MRC5 cells (all
<i>P</i>
<0.01). The GLRX3 protein expressions in blank group, negative control group and experimental group at 48 hours after transfection were 0.311±0.029, 0.328±0.032 and 0.103±0.012, respectively. GLRX3 protein expression level of experimental group in A549 cells was significantly lower than that of control group (
<i>P</i>
<0.01), whilewithout statistical difference between the negative group and blank group (
<i>P</i>
>0.05). A values of experimental group at 24, 48 and 72 hours after transfection in A549 cells were significantly different from those of blank group (all
<i>P</i>
<0.01). Percent of apoptotic cells in the experimental group was (9.52±0.56)%, which was significantly higher than that of blank group [(1.65±0.22)%] and negative control group [(1.42±0.26)%, all
<i>P</i>
<0.01]. Consistently, compared with blank group, the cleaved caspase-3 markedly increased in the experimental group (
<i>P</i>
<0.01). The protein expression of p-STAT3 in the experimental group was significantly lower than the blank group (
<i>P</i>
<0.01), while no significant difference of STAT3 protein expression was observed among all the groups (
<i>P</i>
>0.05).
<b>Conclusions:</b>
Inhibition of GLRX3 gene expression can inhibit the proliferation of lung cancer cells and induce cell apoptosis through up-regulating cleaved caspase-3 expression and down-regulating STAT3 signaling pathway.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">
<PMID Version="1">29860757</PMID>
<DateCompleted>
<Year>2018</Year>
<Month>07</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0253-3766</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>40</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2018</Year>
<Month>May</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>Zhonghua zhong liu za zhi [Chinese journal of oncology]</Title>
<ISOAbbreviation>Zhonghua Zhong Liu Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Proliferation and apoptosis of lung cancer cells regulated by gultaredoxin 3].</ArticleTitle>
<Pagination>
<MedlinePgn>325-329</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.issn.0253-3766.2018.05.002</ELocationID>
<Abstract>
<AbstractText>
<b>Objective:</b>
To investigate the effects of inhibiting glutaredoxin 3(GLRX3) expression on proliferation and apoptosis of lung cancer cells.
<b>Methods:</b>
Western blotting was used to detect the expressions of GLRX3 protein in human embryonic lung fibroblast MRC5 and lung cancer cells, including A427, A549, PC9 and H1299. GLRX3-targeted siRNA (experimental group) and negative siRNA (negative group) were transfected into A549 cells, and the cells without special treatment were blank group. The protein expression levels of GLRX3, cleaved cysteinyl aspartate specific proteinase 3(cleaved caspase-3), signal transducers and activators of transcription 3(STAT3), phosphorylated STAT3(p-STAT3) in each group at 48 hours after transfection were measured by Western blotting. The proliferation ability of differently treated cells at 24 hours, 48 hours and 72 hours after transfection were detected by CCK-8 array. The cell apoptosis at 48 hours after transfection was evaluated by flow cytometry.
<b>Results:</b>
The protein expression levels of GLRX3 in MRC5, A427, A549, PC9 and H1299 were 0.094±0.010, 0.282±0.021, 0.551±0.045, 0.423±0.039 and 0.454±0.036, respectively. The protein expressions of GLRX3 in tested lung cancer cells were significantly higher than that of MRC5 cells (all
<i>P</i>
<0.01). The GLRX3 protein expressions in blank group, negative control group and experimental group at 48 hours after transfection were 0.311±0.029, 0.328±0.032 and 0.103±0.012, respectively. GLRX3 protein expression level of experimental group in A549 cells was significantly lower than that of control group (
<i>P</i>
<0.01), whilewithout statistical difference between the negative group and blank group (
<i>P</i>
>0.05). A values of experimental group at 24, 48 and 72 hours after transfection in A549 cells were significantly different from those of blank group (all
<i>P</i>
<0.01). Percent of apoptotic cells in the experimental group was (9.52±0.56)%, which was significantly higher than that of blank group [(1.65±0.22)%] and negative control group [(1.42±0.26)%, all
<i>P</i>
<0.01]. Consistently, compared with blank group, the cleaved caspase-3 markedly increased in the experimental group (
<i>P</i>
<0.01). The protein expression of p-STAT3 in the experimental group was significantly lower than the blank group (
<i>P</i>
<0.01), while no significant difference of STAT3 protein expression was observed among all the groups (
<i>P</i>
>0.05).
<b>Conclusions:</b>
Inhibition of GLRX3 gene expression can inhibit the proliferation of lung cancer cells and induce cell apoptosis through up-regulating cleaved caspase-3 expression and down-regulating STAT3 signaling pathway.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhu</LastName>
<ForeName>Y Y</ForeName>
<Initials>YY</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wang</LastName>
<ForeName>Z J</ForeName>
<Initials>ZJ</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ma</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>J W</ForeName>
<Initials>JW</Initials>
<AffiliationInfo>
<Affiliation>Department of Oncology, Henan Province People's Hospital/People's Hospital of Zhengzhou University, Zhengzhou 450003, China.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>China</Country>
<MedlineTA>Zhonghua Zhong Liu Za Zhi</MedlineTA>
<NlmUniqueID>7910681</NlmUniqueID>
<ISSNLinking>0253-3766</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C404105">GLRX3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D050796">STAT3 Transcription Factor</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="C505407">CASP3 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D050796" MajorTopicYN="N">STAT3 Transcription Factor</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherAbstract Type="Publisher" Language="chi">
<AbstractText>
<b>目的:</b>
观察抑制谷氧还蛋白3(GLRX3)基因表达对肺癌细胞增殖和凋亡的影响,并探讨其机制。
<b>方法:</b>
Western blot检测人胚肺成纤维细胞MRC5及肺癌A427、A549、PC9、H1299细胞中GLRX3的蛋白表达。采用RNA干扰技术,将合成的GLRX3 siRNA转染A549细胞(实验组),转染阴性siRNA的A549细胞作为阴性组,不经特殊处理的A549细胞为空白组。Western blot检测转染48 h各组细胞中GLRX3、活化的含半胱氨酸的天冬氨酸蛋白水解酶3(cleaved caspase-3)、信号转导与转录因子3(STAT3)和p-STAT3的蛋白表达,细胞计数试剂盒8(CCK-8)法检测转染24、48和72 h细胞的增殖情况,流式细胞术检测转染48 h细胞的凋亡情况。
<b>结果:</b>
人胚肺成纤维细胞MRC5及肺癌A427、A549、PC9、H1299细胞中GLRX3的蛋白表达量分别为0.094±0.010、0.282±0.021、0.551±0.045、0.423±0.039和0.454±0.036,肺癌A427、A549、PC9、H1299细胞中GLRX3的蛋白表达量均显著高于MRC5细胞(均
<i>P</i>
<0.01)。转染A549细胞24、48和72 h,实验组与空白组吸光度差异均有统计学意义(均
<i>P</i>
<0.01)。转染A549细胞48 h,空白组、阴性组和实验组细胞中GLRX3的蛋白表达量分别为0.311±0.029、0.328±0.032和0.103±0.012,实验组显著低于空白组(
<i>P</i>
<0.01),阴性组与空白组差异无统计学意义(
<i>P</i>
>0.05);空白组、阴性组和实验组细胞凋亡率分别为(1.65±0.22)%、(1.42±0.26)%和(9.52±0.56)%,实验组细胞凋亡率显著高于空白组(
<i>P</i>
<0.01);实验组cleaved caspase-3的蛋白表达显著高于空白组(
<i>P</i>
<0.01),p-STAT3的蛋白表达显著低于空白组(
<i>P</i>
<0.01),而STAT3蛋白表达各组间差异无统计学意义(
<i>P</i>
>0.05)。
<b>结论:</b>
抑制GLRX3基因表达,可通过上调cleaved caspase-3的表达、下调STAT3信号通路,抑制肺癌细胞增殖,诱导细胞凋亡。.</AbstractText>
</OtherAbstract>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">Apoptosis</Keyword>
<Keyword MajorTopicYN="N">GLRX3</Keyword>
<Keyword MajorTopicYN="N">Lung neoplasms</Keyword>
<Keyword MajorTopicYN="N">Proliferation</Keyword>
<Keyword MajorTopicYN="N">Signal pathway</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2018</Year>
<Month>6</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2018</Year>
<Month>6</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2018</Year>
<Month>7</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">29860757</ArticleId>
<ArticleId IdType="doi">10.3760/cma.j.issn.0253-3766.2018.05.002</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>République populaire de Chine</li>
</country>
</list>
<tree>
<country name="République populaire de Chine">
<noRegion>
<name sortKey="Zhu, Y Y" sort="Zhu, Y Y" uniqKey="Zhu Y" first="Y Y" last="Zhu">Y Y Zhu</name>
</noRegion>
<name sortKey="Ma, N" sort="Ma, N" uniqKey="Ma N" first="N" last="Ma">N. Ma</name>
<name sortKey="Wang, Z J" sort="Wang, Z J" uniqKey="Wang Z" first="Z J" last="Wang">Z J Wang</name>
<name sortKey="Zhou, J W" sort="Zhou, J W" uniqKey="Zhou J" first="J W" last="Zhou">J W Zhou</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/GlutaredoxinV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000197 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000197 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    GlutaredoxinV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:29860757
   |texte=   [Proliferation and apoptosis of lung cancer cells regulated by gultaredoxin 3].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:29860757" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GlutaredoxinV1 

Wicri

This area was generated with Dilib version V0.6.37.
Data generation: Wed Nov 18 15:13:42 2020. Site generation: Wed Nov 18 15:16:12 2020